MedTrace Logo

Ulipristal Acetate 10 mg and Asisted Reproduction

NCT02425878 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-10-14

No results posted yet for this study

Summary

Demonstrate an 15% increase in the rate of clinical pregnancy in women with inoperable intramural fibroids not distorting the uterine cavity within a program OVD, after administration of uPA in a dose of 10 mg orally daily for 12 weeks

Conditions

  • Intramural Fibroids
  • Uterine Fibroids

Interventions

DRUG

Ulipristal Acetate

DRUG

Placebo

Sponsors & Collaborators

  • Instituto Valenciano de Infertilidad, IVI VALENCIA

    lead OTHER

Principal Investigators

  • Daniela Galliano, MDPhD · Instituto Valenciano de Infertilidad, IVI VALENCIA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-19
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425878 on ClinicalTrials.gov